Tight-control rapid escalation to golimumab induced sustained clinical remission in treatment-naïve early axial spondyloarthritis regardless of microscopic gut inflammation, but most relapsed within 1 year after treatment discontinuation

Tight-control rapid escalation to golimumab induced sustained clinical remission in treatment-naïve early axial spondyloarthritis regardless of microscopic gut inflammation, but most relapsed within 1 year after treatment discontinuation - Notícias Vera Health